Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINHALATIONStandard

XOPENEX HFA

LEVALBUTEROL TARTRATE

Standard Dose
EQ 0.045MG BASE/INH
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview XOPENEX HFA is listed in Drugs@FDA under application 021730 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient LEVALBUTEROL TARTRATE Form and strength AEROSOL, METERED;INHALATION - EQ 0.045MG BASE/INH Sponsor LUPIN Submission history Latest submission status date: 2017-02-27 00:00:00.

Structured Monograph

Clinical summary

Approval overview XOPENEX HFA is listed in Drugs@FDA under application 021730 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient LEVALBUTEROL TARTRATE Form and strength AEROSOL, METERED;INHALATION - EQ 0.045MG BASE/INH Sponsor LUPIN Submission history Latest submission status date: 2017-02-27 00:00:00. Submission type: SUPPL.

Monitoring

  • Marketing status: Prescription
  • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
XOPENEX HFA (LEVALBUTEROL TARTRATE) | Drug Monograph | MedicHelpline